First Site Initiation Visit completed for the PREV-HAP study
The HAP2 team is pleased to announce the successful initiation of the PREV-HAP clinical trial in Nantes, France, in preparation for the recruitment of the first patient to the study.
The first Site Initiation Visit to CHU-Nantes, France, was successfully completed today, under the leadership of Prof. Antoine Roquilly. This event is an important milestone of the project, marking the readiness to promptly begin the recruitment of patients. An extended total of 18 clinical investigational sites have been confirmed and are being contracted (7 in France, 5 in Spain, and 6 in Greece), each of which is scheduled to be activated very soon.